Market Place
Sourcing Support
Nxera Pharma Enrolls 1st Insomnia Patient in Ph 3 Trial
04 Dec 2024 //
GLOBENEWSWIRE
Nxera Pharma Partner Centessa Starts Phase 2 Trial with ORX750
12 Nov 2024 //
GLOBENEWSWIRE
Nxera Pharma & Antiverse Collaborate on AI-Driven GPCR Therapies
05 Nov 2024 //
GLOBENEWSWIRE
Nxera Pharma Reports Q3 & 9-Month 2024 Operational Results
01 Nov 2024 //
GLOBENEWSWIRE
Nxera Pharma Wins Biotech Company and Financing Awards 2024
23 Oct 2024 //
GLOBENEWSWIRE
Nxera Pharma to Host R&D Day 2024
18 Oct 2024 //
GLOBENEWSWIRE
Nxera & Shionogi Partnered For QUVIVIQ Commercialization In Japan
01 Oct 2024 //
GLOBENEWSWIRE
Nxera Pharma Appoints Makoto Sugita As Chief Medical Officer
01 Oct 2024 //
GLOBENEWSWIRE
Nxera Pharma receives approval of insomnia drug in Japan
24 Sep 2024 //
BIOSPECTRUM ASIA
Nxera Pharma`s QUVIVIQ Approved In Japan For Insomnia
23 Sep 2024 //
GLOBENEWSWIRE
Cancer Research UK To Present HTL0039732 Trial At ESMO
13 Sep 2024 //
GLOBENEWSWIRE
Nxera`s Partner Centessa Reports Positive Data For Novel Orexin Agonist
11 Sep 2024 //
GLOBENEWSWIRE
Nxera To Receive $35M From Neurocrine Upon Positive Phase 2 Schizophrenia Data
01 Sep 2024 //
GLOBENEWSWIRE
Nxera Pharma Reports Q2 And H1 2024 Results And Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
09 Jul 2024 //
GLOBENEWSWIRE
Nxera Receives US$10 Million from AbbVie for Neurological Diseases Milestone
26 Jun 2024 //
GLOBENEWSWIRE
Nxera Pharma Publishes Annual And ESG Reports For Year Ended Dec 31, 2023
18 Jun 2024 //
GLOBENEWSWIRE
Nxera To Receive $4.6M Milestones From Centessa
30 May 2024 //
GLOBENEWSWIRE
Nxera, PrecisionLife Expand R&D Tie-Up Into New Therapy Area
30 May 2024 //
GLOBENEWSWIRE
Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering
30 May 2024 //
ENDPTS
Nxera Pharma Q1 2024 Highlights And Consolidated Results
09 May 2024 //
GLOBENEWSWIRE
Nxera Partner Neurocrine Initiates NBI-1117567 Phase 1 Study
09 May 2024 //
GLOBENEWSWIRE
Nxera Pharma Issues New Shares Under RSU Plan
17 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma Notes Successful Progress of Schizophrenia Candidate NBI-1117568
16 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma inks deal with Handok to distribute PIVLAZ in South Korea
16 Apr 2024 //
BIOSPECTRUM ASIA
Nxera Announces Exclusive Supply & Distribution Agreement with Handok for PIVLAZ
14 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma joins the World Orphan Drug Alliance
08 Apr 2024 //
GLOBENEWSWIRE
WODA Expands to Japan & South Korea and the African Subcontinent
08 Apr 2024 //
GLOBENEWSWIRE
Nxera Appoints Patrick Branch as Head of Business Development for Japan and APAC
03 Apr 2024 //
GLOBENEWSWIRE
Nxera Pharma is the New Name for Sosei Group
31 Mar 2024 //
GLOBENEWSWIRE
Sosei Heptares Regains Full Ownership from GSK of HTL0027477 IBD
20 Mar 2024 //
GLOBENEWSWIRE
Sosei Heptares Doses First Subject Ph 1 Trial HTL0033744, EP4 Agonist for IBD
20 Mar 2024 //
GLOBENEWSWIRE
Report of transactions of shares and related securities of Bavarian Nordic
06 Mar 2024 //
GLOBENEWSWIRE
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma
15 Feb 2024 //
GLOBENEWSWIRE
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months
13 Feb 2024 //
GLOBENEWSWIRE
Sosei Heptares Webinar Presentation for FY2023 Financial Results
22 Jan 2024 //
GLOBENEWSWIRE
Sosei Group Announces Appointment of Toshihiro Maeda as Chief Operating Officer
05 Jan 2024 //
GLOBENEWSWIRE
Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
Sosei Group Announces Marketing Approval for PIVLAZ 150 mg in South Korea
07 Dec 2023 //
GLOBENEWSWIRE
Neurocrine Confirms Plans to Evaluate Muscarinic Agonist Candidates in Ph 1 Studies
06 Dec 2023 //
GLOBENEWSWIRE
Sosei Heptares to Regain Full Ownership of GSK4381406
25 Nov 2023 //
GLOBENEWSWIRE
Sosei Heptares Highlights and Consolidated Results for the Third Quarter
10 Nov 2023 //
GLOBENEWSWIRE
Sosei & Kallyope Nominate First GPCR Target for Gastrointestinal
10 Nov 2023 //
GLOBENEWSWIRE
Sosei Heptares™ President & CEO to Participate in Healthcare Conference 2023
07 Nov 2023 //
GLOBENEWSWIRE
Sosei Heptares Partner, Pfizer, Progresses GLP-1 Receptor Agonist PF-06954522
05 Nov 2023 //
GLOBENEWSWIRE
Sosei Announces Submission of New Drug Application in Japan for Daridorexant
31 Oct 2023 //
GLOBENEWSWIRE
Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
31 Oct 2023 //
GLOBENEWSWIRE
Sosei Heptares to Host R&D Day Highlighting its Innovative R&D
25 Oct 2023 //
GLOBENEWSWIRE
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
10 Oct 2023 //
GLOBENEWSWIRE
Sosei Heptares acquires Idorsia`s pharma business in Japan and beyond
21 Jul 2023 //
THE PHARMA LETTER
Sosei Heptares Provides Update on Lotiglipron Development
26 Jun 2023 //
GLOBENEWSWIRE
Sosei Heptares Operational Highlights and Consolidated Results for Q1 2023
12 May 2023 //
GLOBENEWSWIRE
Sosei Heptares Confirms Changes to its Board and Executive Management Team
23 Mar 2023 //
GLOBENEWSWIRE
Sosei Announces Change of Market Listing Segment
14 Mar 2023 //
GLOBENEWSWIRE
Sosei Heptares Receives Approval for Change of Market Listing Segment
08 Mar 2023 //
GLOBENEWSWIRE
Sosei Operational Highlights Results for 12 Months ended 31 December 2022
14 Feb 2023 //
GLOBENEWSWIRE
Sosei Heptares Webinar Presentation for FY2022 Financial Results
25 Jan 2023 //
GLOBENEWSWIRE
Sosei Notes its Partner Tempero has Received FDA Clearance for TMP-301
05 Jan 2023 //
GLOBENEWSWIRE
Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
20 Dec 2022 //
GLOBENEWSWIRE
Sosei Heptares Receives $10 M Payment in Discovery Collaboration with AbbVie
12 Dec 2022 //
GLOBENEWSWIRE
